Literature DB >> 7889638

Megestrol-induced Cushing's syndrome.

K A Steer1, A B Kurtz, J W Honour.   

Abstract

This case describes the first report of a patient developing Cushing's syndrome whilst being treated with the synthetic progestogen, megestrol acetate (Megace). Drugs are the commonest cause of Cushing's syndrome. Some synthetic progestogens are known to have glucocorticoid activity at high doses. On structural grounds neither megestrol nor its major metabolites would be expected to interact with the glucocorticoid receptor, through the manufacturers report that it may have 'weak glucocorticoid activity'.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7889638     DOI: 10.1111/j.1365-2265.1995.tb02603.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  4 in total

Review 1.  Managing cancer-related anorexia/cachexia.

Authors:  G Mantovani; A Macciò; E Massa; C Madeddu
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 2.  A review of the drug treatment of cachexia associated with cancer.

Authors:  B Gagnon; E Bruera
Journal:  Drugs       Date:  1998-05       Impact factor: 9.546

3.  High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate.

Authors:  A R Chidakel; S B Zweig; J R Schlosser; P Homel; J W Schappert; A M Fleckman
Journal:  J Endocrinol Invest       Date:  2006-02       Impact factor: 4.256

4.  Megace Mystery: A Case of Central Adrenal Insufficiency.

Authors:  Kunal Mehta; Irene Weiss; Michael D Goldberg
Journal:  Case Rep Endocrinol       Date:  2015-12-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.